25C-NBOH
25C-NBOH is a synthetic psychedelic of the substituted phenethylamine class, produced through N-benzylation of the psychedelic 2C-C.1 First synthesized in 2011 by Martin Hansen at the University of Copenhagen, it has since appeared as a designer drug.1 It is known for producing predominantly visual and stimulating psychedelic effects, with serotonin receptor affinity comparable to its structural relative 25C-NBOMe.
Contents
Dosage & Duration
Dosage
The NBOH family lacks oral bioavailability and requires sublingual administration. The substance must be held in the mouth for 15-25 minutes to permit absorption. Users consistently report an acrid metallic taste and pronounced oral numbness persisting approximately one hour post-absorption. The compound exhibits a highly sensitive dose-response curve with unpredictable subjective effects reported even at similar dosage levels. Insufflation is contraindicated due to documented severe adverse outcomes, including deaths and hospitalizations, associated with closely related NBOMe compounds using this administration route.
Duration
Subjective Effects
25C-NBOH produces a stimulating psychedelic experience broadly typical of the NBOH series, combining euphoria, empathy, and a general alteration of perception with prominent visual effects visible with both open and closed eyes. The headspace tends toward insight and a softening of ego boundaries, though confusion can occur, and mental and physical stimulation often persists long enough to interfere with sleep.
Physical
The body experience is distinctly stimulating and can include restlessness, muscle tension, and alternating sweating and chills. Appetite is suppressed, pupils dilate, and insomnia is common while effects remain active.
Stimulation
Stimulation is both mental and physical, and can manifest as restlessness.
Uncomfortable
Cognitive
The mental state is euphoric and empathogenic, with an insight-oriented, introspective character and a softening of the sense of self. Confusion is reported by some users, particularly as perception becomes more altered.
Emotional
Visual
Visual effects are a core feature of the experience, spanning brightened colors and visuals that appear with eyes both open and closed.
Tactile
Tactile sensation is enhanced, with touch and texture feeling more pronounced.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
25C-NBOH acts as a potent agonist at serotonin 5-HT2A receptors, with a pEC50 value of 9.43, making it one of the most selective agonist ligands known for this receptor.2 It also displays affinity at 5-HT2C receptors, though to a lesser extent. Its unusually high selectivity for serotonin receptors distinguishes it pharmacologically among psychedelic phenethylamines.
Pharmacokinetics
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely Low25C-NBOH is generally not regarded as habit forming, and repeated use may make taking it again less appealing. Its use is usually self-limiting rather than reinforcing.
Physical
Extremely LowNo evidence of physical dependence or withdrawal symptoms has been documented.
Toxicity
Temperature regulation suppression and increased body temperature occur during intoxication, which may contribute to dangerous hyperthermia, particularly at high doses or in warm environments with physical activity.3
Psychosis Risk
Anxiety and paranoia appear to occur more readily with 25C-NBOH than with many other psychedelics, possibly related to its stimulating properties. At high doses, confusion, amnesia, and sensory overload may occur, potentially increasing vulnerability to adverse psychological reactions.
Seizure Risk
Seizures are documented as a possible effect.35 The unpredictable dose-response relationship of this substance may contribute to seizure risk at unexpectedly high effect levels.
History & Culture
25C-NBOH was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen. The compound is a derivative of the phenethylamine psychedelic 2C-C,1 distinguished by the addition of an N-benzyl group bearing a hydroxyl substituent on the…
Legality
By Country
References
Source Pages
Citations
- (2019). Identification of new NBOH drugs in seized blotter papers: 25B-NBOH, 25C-NBOH, and 25E-NBOH. Forensic Toxicology, 38(2), 203–215. https://doi.org/10.1007/s11419-019-00509-71234
- (March 2014). Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5(3), 243–9. https://doi.org/10.1021/cn400216u12
- Halberstadt AL, Chatha M, Klein AK, Wallach J, & Brandt SD. (2020). NBOMes-Highly Potent and Toxic Alternatives of LSD. https://doi.org/10.3389/fnins.2020.000781234
- Tang MHY, Ching CK, Tsui MSH, Chu FKC, & Mak TWL. (2014). Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. 52(5), 561-565. https://doi.org/10.3109/15563650.2014.90993212
- Wood DM, Sedefov R, Cunningham A, & Dargan PI. (2015). Prevalence of use and acute toxicity associated with the use of NBOMe drugs. 53(2), 85-92. https://doi.org/10.3109/15563650.2015.1004179123
- Agência Nacional de Vigilância Sanitária (ANVISA). (2018-12-10). Resolução da Diretoria Colegiada - RDC Nº 254, DE 10 DE DEZEMBRO DE 2018. Ministério da Saúde / ANVISA. https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2018/rdc0254_10_12_2018.pdf1
- Bundesministerium der Justiz und für Verbraucherschutz. (2016-11-26). Neue-psychoaktive-Stoffe-Gesetz (NpSG). Bundesministerium der Justiz und für Verbraucherschutz. https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- (2019). § 4 NpSG. https://www.gesetze-im-internet.de/npsg/__4.html1
- Eidgenössisches Departement des Innern (EDI). (2011-05-30). Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI). Schweizerische Eidgenossenschaft / Fedlex. https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20250515/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-363-20250515-de-pdf-a.pdf1
- (1971). Misuse of Drugs Act 1971 (S.I. 2014/1106). https://www.legislation.gov.uk/uksi/2014/1106/made1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25C-NBOH article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.